Status:
UNKNOWN
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells in Ischemic Stroke
Lead Sponsor:
Instituto de Investigación Hospital Universitario La Paz
Conditions:
Ischemic Stroke
Adipose Tissue-derived Stem Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a multicenter, doble blind, placebo controlled clinical trial to asses de safety and efficacy of intravenous administration of alogenic adipose tissue-derived mesenchymal stem cells in the fir...
Detailed Description
Two spanish hospitals with teams experienced in stroke management will participate in this study, recruiting a total of 30 patients between them both. After confirming that patients fulfill the inclus...
Eligibility Criteria
Inclusion
- Ischemic stroke patients \> 18 years old
- Patients must be able to be treated within the first 4 days (+/- 1) from acute stroke symptoms onset. If the time of symptom onset is unknown, this shall refer to the last time the patient was observed as asymptomatic.
- A computed tomography (CT) or magnetic resonance imaging (MRI) scan compatible with the clinical diagnosis of acute non-lacunar IS in the region of the middle cerebral artery (with cortical or subcortical involvement).
- A score on the National Institute of Health Stroke Scale (NIHSS) of 8-20, with at least two of these points in sections 5 and 6 (motor deficit) at the time of inclusion. NIHSS evaluation for screening of these patients will take place after finalization of reperfusion therapies (if they have been performed) providing that the clinical condition of the patient is stable with no prevision of immediate recovery. A measurable focal neurologic disabilty must persist to the time of treatment.
- A prestroke score on the Modified Rankin Scale (mRS) ≤1 (no significant disability).
- Female subjects non-child bearing potential. Female subjects who are of non-childbearing potential are defined as meeting at least 1 of the following criteria:
- Have undergone a documented hysterectomy and/or bilateral oophorectomy; Have medically confirmed ovarian failure; or Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause.
- Female subjects of child-bearing potential need a negative pregnancy test and must agree to use adequate contraception for the duration of the study (from screening through the final of the study). The following types of contraception are considered adequate provided they are locally authorized for use: oral, transdermal, or injectable (depot) estrogen and/or progestogen, selective estrogen receptor modulator therapy, intrauterine contraceptive device, double barrier method (e.g., condom and diaphragm or spermicidal gel) or vasectomy.
- Signed informed consent
Exclusion
- Comatose patients; patients with a score of 2 or more on item 1a of the NIHSS related to the degree of awareness.
- Evidence on neuroimaging of brain tumour, cerebral oedema with midline shift and a clinically significant compression of ventricles, cerebellar or brainstem infarction and intraventricular, intracerebral or subarachnoid haemorrhage. Small petechial haemorrhages are not exclusion criteria.
- Current drug or alcohol use or dependence
- Active infectious disease, including human immunodeficiency virus, hepatitis B, and hepatitis C. A controlled infection is not an exclusion criterion.
- Pre-existing dementia.
- A health status, any clinical condition (eg, short life expectancy, and coexisting disease or a surgical or endovascular planned procedure) or other characteristic that precludes appropriate diagnosis, treatment, or follow-up in the trial.
- Patients who are participating in another clinical trial.
- Inability or unwillingness of the individual or their legal guardian/representative to provide written informed consent.
Key Trial Info
Start Date :
January 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 15 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04280003
Start Date
January 20 2021
End Date
July 15 2023
Last Update
May 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario La Paz
Madrid, Spain, 28046